頁籤選單縮合
題名 | SODAS劑型應用於Methylphenidate HCl之剖析=SODAS Formulation Applied to the Analysis of Methylphenidate HCl |
---|---|
作者姓名(中文) | 古貞庭; | 書刊名 | 藥學雜誌 |
卷期 | 31:2=123 2015.06[民104.06] |
頁次 | 頁43-49 |
分類號 | 418.21 |
關鍵詞 | 注意力不足/過動症; 口服圓粒藥物吸收系統; 精神興奮劑; Methylphenidate; Psychostimulants; |
語文 | 中文(Chinese) |
中文摘要 | 注意力不足/過動症 (Attention Deficit/Hyperactivity Disorder, ADHD) 的治療可分為 藥物治療、行為治療與藥物治療合併行為治療三大類;美國國立衛生研究院 (National Institutes of Health, NIH) 於 ADHD 治療指引指出,藥物治療合併行為治療與單獨使用 藥物治療控制 ADHD 症狀的效果相當,且遠優於行為治療;藥物治療合併行為治療 對於非 ADHD 核心症狀的改善則有更佳的效果。 目前國內核准的 ADHD 治療藥物有 methylphenidate (MPH) 與 atomoxetine 兩種, 其中 methylphenidate 在藥理分類上屬於精神興奮劑 (psychostimulants),是國內外治療 兒童 ADHD 的主要藥物,因其作用時間僅約4小時,故劑型上又可分為一般劑型 (IRMPH) 與長效劑型 (ER-MPH) 兩種。 口服圓粒藥物吸收系統 (Spheroidal Oral Drug Absorption System;SODAS) 是由 Elan 公司所研發之多重顆粒 (multiparticulate technology) 技術,其中包含了速效型 (immediate release) 與持續釋放型顆粒 (sustained release);速效型顆粒具有快速作用的 效果,持續釋放型顆粒則可在服用藥物經過特定的時間之後再將藥物釋放出來,達到 與服用2次藥物相近的血中藥物濃度曲線。 ER-MPH 不同的緩釋技術,呈現不同的藥物動力學特性與療效;並沒有一個 ERMPH 製劑的療效明顯地優於其它製劑,選擇 ER-MPH 製劑最重要的考量應該是以各 種患者治療需求為出發點,為病人選擇最適合的製劑。 |
英文摘要 | Attention Deficit/Hyperactivity Disorder, ADHD) treatment can be divided into drug treatment, behavioral therapy and behavioral therapy medication merge three categories;NIH (National Institutes of Health, NIH) in ADHD treatment guidelines point out that the combined medication and behavioral therapy alone medication to control the symptoms of ADHD quite effective, and far superior to behavioral therapy; medication merge nonbehavioral therapy to improve the core symptoms of ADHD, there are better results. There are domestic approved ADHD drugs methylphenidate (MPH) and atomoxetine are two of them belong to the psychostimulant methylphenidate on pharmacological classification (psychostimulants), is home to the main drug treatment of children with ADHD, because of its duration of action is only about four hours, can be divided into general formulations (IRMPH) and long-acting formulation (ER-MPH) two kinds of forms on it. Spheroidal Oral Drug Absorption System (SODAS) is a multi-particle developed by Elan Corporation, plc's multiparticulate technology, which includes the immediate release and sustained-release, fast-acting effect of the particles have a fast-acting, sustained release particles may be taking drugs after a certain time and then the drug release, the drug to reach and close to twice the blood drug concentration profile taken. ER-MPH different sustained-release technology, show different dynamics and efficacy of the drug; and there is no effect of ER-MPH formulations significantly better than other agents, select ER-MPH formulations of the most important considerations should be based on a variety of patients demand as the starting point, select the most appropriate formulation for patients. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。